USA - NASDAQ:PYPD - IL0011326795 - Common Stock
The current stock price of PYPD is 3.63 USD. In the past month the price increased by 13.59%. In the past year, price increased by 2.54%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.12 | 980.74B | ||
| JNJ | JOHNSON & JOHNSON | 19.26 | 481.42B | ||
| MRK | MERCK & CO. INC. | 10.98 | 241.66B | ||
| PFE | PFIZER INC | 7.95 | 144.73B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.2 | 96.16B | ||
| ZTS | ZOETIS INC | 18.68 | 52.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.6 | 23.02B | ||
| VTRS | VIATRIS INC | 4.62 | 12.54B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.32 | 10.65B | ||
| CORT | CORCEPT THERAPEUTICS INC | 84.14 | 7.80B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.38B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.07B |
PolyPid Ltd. operates as a phase 3 biopharma company. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
POLYPID LTD
18 Hasivim Street, P.O Box 7126
Petah Tikva 49537 IL
CEO: Amir Weisberg
Employees: 57
Phone: 972747195700
PolyPid Ltd. operates as a phase 3 biopharma company. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
The current stock price of PYPD is 3.63 USD.
PYPD does not pay a dividend.
PYPD has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
POLYPID LTD (PYPD) operates in the Health Care sector and the Pharmaceuticals industry.
POLYPID LTD (PYPD) will report earnings on 2026-02-10, after the market close.
The outstanding short interest for POLYPID LTD (PYPD) is 0.67% of its float.
ChartMill assigns a technical rating of 7 / 10 to PYPD. When comparing the yearly performance of all stocks, PYPD turns out to be only a medium performer in the overall market: it outperformed 62.62% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to PYPD. While PYPD seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months PYPD reported a non-GAAP Earnings per Share(EPS) of -2.94. The EPS increased by 62.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -91.61% | ||
| ROE | -168.61% | ||
| Debt/Equity | 0 |
10 analysts have analysed PYPD and the average price target is 12.5 USD. This implies a price increase of 244.21% is expected in the next year compared to the current price of 3.63.